Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


09.10.2017

1 AJR Am J Roentgenol
1 Am J Clin Pathol
1 Am J Pathol
11 Anticancer Res
3 Br J Cancer
2 Breast Cancer (Auckl)
1 Breast Cancer Res
2 Breast Cancer Res Treat
1 Cancer Epidemiol Biomarkers Prev
3 Cancer Lett
1 Cancer Res
2 Carcinogenesis
3 Clin Cancer Res
1 Int J Cancer
2 J Clin Oncol
1 J Natl Cancer Inst
1 J Pathol
1 J Surg Oncol
1 JAMA
1 Lancet Oncol
2 Mod Pathol
1 NPJ Breast Cancer
1 PLoS Genet
3 PLoS One
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. BROWN AL, Phillips J, Slanetz PJ, Fein-Zachary V, et al
    Clinical Value of Mammography in the Evaluation of Palpable Breast Lumps in Women 30 Years Old and Older.
    AJR Am J Roentgenol. 2017 Aug 4:1-8. doi: 10.2214/AJR.16.17088.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. HOU Y, Zynger DL, Li X, Li Z, et al
    Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
    Am J Clin Pathol. 2017;148:167-172.
    PubMed     Text format     Abstract available


    Am J Pathol

  3. GEYER FC, Pareja F, Weigelt B, Rakha E, et al
    The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.
    Am J Pathol. 2017;187:2139-2151.
    PubMed     Text format     Abstract available


    Anticancer Res

  4. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available

  5. HARUNA F, Lipsett A, Marignol L
    Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:5343-5353.
    PubMed     Text format     Abstract available

  6. GIGLI S, Amabile MI, DI Pastena F, DE Luca A, et al
    Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature.
    Anticancer Res. 2017;37:5395-5398.
    PubMed     Text format     Abstract available

  7. CALIS IU, Cosan DT, Mutlu F
    Effects of S1P1 and S1P3 in ER+ and ER- Breast Cancer Cells.
    Anticancer Res. 2017;37:5469-5475.
    PubMed     Text format     Abstract available

  8. BOBIN-DUBIGEON C, Chauvin A, Brillaud-Meflah V, Boiffard F, et al
    Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.
    Anticancer Res. 2017;37:5495-5498.
    PubMed     Text format     Abstract available

  9. PHAM DH, Kim JS, Kim SK, Shin DJ, et al
    Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:5507-5513.
    PubMed     Text format     Abstract available

  10. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (>/=70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Anticancer Res. 2017;37:5585-5594.
    PubMed     Text format     Abstract available

  11. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:5623-5630.
    PubMed     Text format     Abstract available

  12. HE K, Wang X, Guan X, Yu Q, et al
    Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2017;37:5647-5653.
    PubMed     Text format     Abstract available

  13. KARMAKAR MK, Samy W, Lee A, Li JW, et al
    Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial.
    Anticancer Res. 2017;37:5813-5820.
    PubMed     Text format     Abstract available

  14. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


    Br J Cancer

  15. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Text format     Abstract available

  16. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available

  17. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  18. COHEN IJ, Blasberg R
    Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer.
    Breast Cancer (Auckl). 2017;11:1178223417731565.
    PubMed     Text format     Abstract available

  19. TANAKA H, Ito M, Yamaguchi T, Hachiya K, et al
    High Tangent Radiation Therapy With Field-in-Field Technique for Breast Cancer.
    Breast Cancer (Auckl). 2017;11:1178223417731297.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  20. TU CF, Wu MY, Lin YC, Kannagi R, et al
    FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation.
    Breast Cancer Res. 2017;19:111.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  21. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Text format     Abstract available

  22. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  23. DEAN LT, Moss SL, McCarthy AM, Armstrong K, et al
    Healthcare System Distrust, Physician Trust, and Patient Discordance with Adjuvant Breast Cancer Treatment Recommendations.
    Cancer Epidemiol Biomarkers Prev. 2017 Sep 29. pii: cebp.0479.2017.
    PubMed     Text format     Abstract available


    Cancer Lett

  24. XU H, Lin F, Wang Z, Yang L, et al
    CXCR2 Promotes Breast Cancer Metastasis and Chemoresistance via suppression of AKT1 and activation of COX2.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30583.
    PubMed     Text format     Abstract available

  25. OLADAPO HO, Tarpley M, Sauer SJ, Addo KA, et al
    Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30586.
    PubMed     Text format     Abstract available

  26. MARINO S, Bishop RT, Logan JG, Mollat P, et al
    Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30587.
    PubMed     Text format     Abstract available


    Cancer Res

  27. ISHIHARA S, Inman DR, Li WJ, Ponik SM, et al
    Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells.
    Cancer Res. 2017 Sep 28. pii: canres.0569.2017.
    PubMed     Text format     Abstract available


    Carcinogenesis

  28. FRANCESCHI S, Spugnesi L, Aretini P, Lessi F, et al
    Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Carcinogenesis. 2017;38:938-943.
    PubMed     Text format     Abstract available

  29. LI SS, Xu LZ, Zhou W, Yao S, et al
    p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis.
    Carcinogenesis. 2017 Sep 12. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  30. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    PubMed     Text format     Abstract available

  31. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    PubMed     Text format     Abstract available

  32. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    PubMed     Text format     Abstract available


    Int J Cancer

  33. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Text format     Abstract available


    J Clin Oncol

  34. GOETZ MP, Toi M, Campone M, Sohn J, et al
    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
    PubMed     Text format     Abstract available

  35. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
    Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
    J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  36. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    J Pathol

  37. OLIEMULLER E, Kogata N, Bland P, Kriplani D, et al
    SOX11 promotes invasive growth and ductal carcinoma in situ progression.
    J Pathol. 2017;243:193-207.
    PubMed     Text format     Abstract available


    J Surg Oncol

  38. ALTUNDAG K
    Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    J Surg Oncol. 2017 Oct 2. doi: 10.1002/jso.24839.
    PubMed     Text format    


    JAMA

  39. SLOMSKI A
    Low-Fat Diet Reduces Mortality After Breast Cancer.
    JAMA. 2017;318:1099.
    PubMed     Text format    


    Lancet Oncol

  40. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
    Resource-stratified implementation of a community-based breast cancer management programme in Peru.
    Lancet Oncol. 2017;18:e607-e617.
    PubMed     Text format     Abstract available


    Mod Pathol

  41. ADAMS TA, Vail PJ, Ruiz A, Mollaee M, et al
    Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

  42. SANCHEZ-MUNOZ A, Vicioso L, Santonja A, Alvarez M, et al
    Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  43. OH H, Eliassen AH, Beck AH, Rosner B, et al
    Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue.
    NPJ Breast Cancer. 2017;3:39.
    PubMed     Text format     Abstract available


    PLoS Genet

  44. CAIRNS J, Ingle JN, Wickerham LD, Weinshilboum R, et al
    SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERalpha-positive breast cancer through regulation of BRCA1.
    PLoS Genet. 2017;13:e1007031.
    PubMed     Text format     Abstract available


    PLoS One

  45. MARQUEZ-RODAS I, Pollan M, Escudero MJ, Ruiz A, et al
    Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Alamo III" retrospective study.
    PLoS One. 2017;12:e0184181.
    PubMed     Text format     Abstract available

  46. CILEK EE, Ozturk H, Gur Dedeoglu B
    Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines.
    PLoS One. 2017;12:e0185558.
    PubMed     Text format     Abstract available

  47. AUKES K, Forsman C, Brady NJ, Astleford K, et al
    Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions.
    PLoS One. 2017;12:e0185736.
    PubMed     Text format     Abstract available


    Radiother Oncol

  48. HANS S, Cottu P, Kirova YM
    Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.
    Radiother Oncol. 2017 Sep 27. pii: S0167-8140(17)32577.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: